Webinar: What's next for prostate cancer research
Join this webinar to better understand what we do and don’t know about how to treat localised prostate cancer. Learn about these ongoing studies from the researchers and what their findings could mean for the future of prostate cancer care.
Organiser | National Institute for Health and Care Research (NIHR) |
---|
Prostate cancer is the most common cancer in men, with more than 55,000 newly diagnosed each year in the UK. Men with localised cancer (confined to the prostate) are likely to live for a long time.
Based on findings from the landmark NIHR trial (ProtecT), national guidelines recommend that men with lower risk localised cancer are offered a choice of: active surveillance (regular monitoring), surgery or radiotherapy.
For the future, research is looking for ways to optimise care. This webinar brings together 3 large, ongoing NIHR randomised controlled trials involving men with localised cancer. The trials ask whether:
- regular MRI scans improve active surveillance in low to medium risk prostate cancer compared to standard care
- treating only the part of the prostate containing the cancer is as effective as treating the whole prostate, and has fewer side effects, for medium risk cancer
- it is beneficial to remove lymph nodes as well as the prostate in high risk cancer.
Presenters:
Archana Gopalakrishnan, Clinical Research Fellow (Urology), Imperial College London.
Richard Bryant, Associate Professor and Consultant Urologist, University of Oxford.
Krishna Narahari, Professor and Consultant Urologist, University Hospital of Wales, Cardiff.
Contact our organiser
National Institute for Health and Care Research (NIHR)
Email: martha.powell@nihr.ac.uk